

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use MANNITOL INJECTION safely and effectively. See full prescribing information for MANNITOL INJECTION.

MANNITOL injection, for intravenous use

Initial U.S. Approval: 1964

RECENT MAJOR CHANGES

Indications and Usage (removed, revised) (1)	04/2020
Contraindications (4)	04/2020
Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7)	04/2020

INDICATIONS AND USAGE

Mannitol Injection is an osmotic diuretic indicated for the reduction of:

- intracranial pressure and treatment of cerebral edema. (1)
- elevated intraocular pressure. (1)

DOSAGE AND ADMINISTRATION

Administration Instructions (2.1):

- For intravenous infusion preferably into a large central vein.
- Prior to administration, evaluate renal, cardiac and pulmonary status, and correct fluid and electrolyte imbalances.

Recommended Dosage (2.2):

- The dosage, concentration and rate of administration depend on the age, weight and condition of the patient, including fluid requirement, urinary output and concomitant therapy.
- *Reduction of Intracranial Pressure:* 0.25 g/kg administered every 6 to 8 hours as an intravenous infusion over at least 30 minutes.
- *Reduction of Intraocular Pressure:* 1.5 to 2 g/kg as a single dose administered intravenously over at least 30 minutes. Administer 60 to 90 minutes before surgery to achieve maximal effect.

DOSAGE FORMS AND STRENGTHS

Injection: 20% (0.2 grams/mL); 20 grams of mannitol, USP per 100 mL in single-dose 250 mL and 500 mL flexible containers (3)

CONTRAINDICATIONS

- Known hypersensitivity to mannitol. (4, 5.1)
- Anuria. (4, 5.2)
- Severe hypovolemia. (4, 5.4)
- Pre-existing pulmonary vascular congestion or pulmonary edema. (4, 5.5)
- Active intracranial bleeding except during craniotomy. (4)

WARNINGS AND PRECAUTIONS

- **Hypersensitivity Reactions, including anaphylaxis:** Stop infusion immediately if hypersensitivity reactions develop. (5.1)
- **Renal Complications Including Renal Failure:** Risk factors include preexisting renal failure, concomitant use of nephrotoxic drugs or other

diuretics. Avoid use of nephrotoxic drugs. Discontinue Mannitol Injection if renal function worsens. (5.2, 8.6)

- **Central Nervous System (CNS) Toxicity:** Confusion, lethargy and coma may occur during or after infusion. Concomitant neurotoxic drugs may potentiate toxicity. Avoid use of neurotoxic drugs. Discontinue Mannitol Injection if CNS toxicity develops. (5.3)
- **Fluid and Electrolyte Imbalances, Hyperosmolarity:** Hypervolemia may exacerbate congestive heart failure, hyponatremia can lead to encephalopathy; hypo/hyperkalemia can result in cardiac adverse reactions in sensitive patients. Discontinue Mannitol Injection if fluid and/or electrolyte imbalances occur. (5.4)
- **Monitoring/Laboratory Tests:** Monitor fluid and electrolytes, serum osmolality and renal, cardiac and pulmonary function. Discontinue if toxicity develops. (5.5)
- **Infusion Site Reactions:** May include irritation and inflammation, as well as severe reactions (compartment syndrome) when associated with extravasation. (5.6)
- **Interference with Laboratory Tests:** High concentrations of mannitol may cause false low results of inorganic phosphorus blood concentrations. Mannitol may produce false positive results for blood ethylene glycol. (5.7, 7.6)

ADVERSE REACTIONS

The most common adverse reactions are hypersensitivity reactions, renal failure, CNS toxicity, hypo/hypervolemia, hypo/hyponatremia, hypo/hyperkalemia, and infusion site reactions. (6)

To report SUSPECTED ADVERSE REACTIONS, contact name ICU Medical, Inc. at 1-800-441-4100 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- **Nephrotoxic Drugs and Diuretics:** May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2)
- **Neurotoxic Drugs:** May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3)
- **Drugs Affected by Electrolyte Imbalances:** May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4)
- **Renally Eliminated Agents:** Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 04/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Preparation and Administration Instructions
- 2.2 Recommended Dosage

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Hypersensitivity Reactions
- 5.2 Renal Complications Including Renal Failure
- 5.3 Central Nervous System (CNS) Toxicity
- 5.4 Fluid and Electrolyte Imbalances, Hyperosmolarity
- 5.5 Monitoring/Laboratory Tests
- 5.6 Infusion Site Reactions
- 5.7 Interference with Laboratory Tests

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

- 7.1 Nephrotoxic Drugs
- 7.2 Diuretics

7.3 Neurotoxic Drugs

7.4 Drugs Affected by Electrolyte Imbalances

7.5 Renally Eliminated Drugs

7.6 Interference with Laboratory Tests

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacokinetics

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Mannitol Injection is indicated for the reduction of:

- intracranial pressure and treatment of cerebral edema;
- elevated intraocular pressure.

2 DOSAGE AND ADMINISTRATION

2.1 Important Preparation and Administration Instructions

- Mannitol Injection is for intravenous infusion preferably into a large central vein [*see Warnings and Precautions (5.6), Description (11)*].
- Prior to administration of Mannitol Injection, evaluate renal, cardiac, and pulmonary status of the patient and correct fluid and electrolyte imbalances [*see Dosage and Administration (2.2)*].
- Do not administer Mannitol Injection simultaneously with blood products through the same administration set because of the possibility of pseudoagglutination or hemolysis.

Preparation

1. Tear outer wrap at notch and remove solution container.
2. Visually inspect flexible container. Do not administer unless the solution is clear and the seal is intact.
 - If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired.
 - Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.
3. Check for minute leaks prior to use by squeezing the bag firmly. If leaks are detected, discard solution as sterility may be impaired.
4. Admixing Mannitol Injection with other medications is not recommended.
5. Inspect Mannitol Injection visually for particulate matter and discoloration prior to administration. If particulates or discoloration are present, discard the bag.

Mannitol Injection solutions may crystallize when exposed to low temperatures. Inspect Mannitol Injection for crystals prior to administration. If crystals are visible, re-dissolve by warming the solution up to 70°C with agitation. Heat solution by using a dry-heat cabinet with overwrap intact. The use of a water bath is not recommended. Allow the solution to cool to body temperature or less before administering. Reinspect Mannitol Injection for crystals prior to administration. Discard the solution if all the crystals cannot be dissolved.

Administration

1. Close flow control clamp of administration set.
2. Remove cover from outlet port at bottom of container.
3. Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. *NOTE:* See full directions on administration set carton.

4. Use administration sets with a final in-line filter because of the potential for mannitol crystals to form.
5. Suspend container from hanger.
6. Squeeze and release drip chamber to establish proper fluid level in chamber.
7. Open flow control clamp and clear air from set. Close clamp.
8. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.
9. Regulate rate of administration with flow control clamp.
10. To prevent air embolism, use a non-vented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible containers in series, fully evacuate residual gas in the container prior to administration, do not pressurize the flexible container to increase flow rates, and if administration is controlled by pumping device, turn off pump before the container runs dry.
11. For single use only; discard unused portion.

2.2 Recommended Dosage

Prior to administration of Mannitol Injection, evaluate renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances.

The total dosage, concentration, and rate of administration depend on the age, weight, and condition of the patient being treated, including fluid requirement, electrolyte balance, serum osmolality, urinary output, and concomitant therapy.

The following outline of administration and dosage is only a general guide to therapy.

Reduction of Intracranial Pressure and Treatment of Cerebral Edema

Usually a maximum reduction in intracranial pressure can be achieved with a dose of 0.25 gram/kg given intravenously as an intravenous infusion over at least 30 minutes, which may be repeated every six to eight hours.

During and following Mannitol Injection infusion, monitor fluid and electrolytes, serum osmolarity, and renal, cardiac and pulmonary function. Discontinue Mannitol Injection if renal, cardiac, or pulmonary status worsens or CNS toxicity develops [see *Warnings and Precautions (5.2, 5.3, 5.4, 5.5)*].

Reduction of Intraocular Pressure

The recommended dosage is 1.5 to 2 g/kg as a single dose administered as an intravenous infusion over at least 30 minutes. When used preoperatively, administer Mannitol Injection 60 to 90 minutes before surgery to achieve maximal reduction of intraocular pressure before operation.

3 DOSAGE FORMS AND STRENGTHS

Injection: 20% (0.2 grams/mL); 20 grams of mannitol, USP per 100 mL as a clear and colorless solution in single-dose 250 mL and 500 mL flexible containers

4 CONTRAINDICATIONS

Mannitol Injection is contraindicated in patients with:

- Known hypersensitivity to mannitol [see *Warnings and Precautions (5.1)*]
- Anuria [see *Warnings and Precautions (5.2)*]
- Severe hypovolemia [see *Warnings and Precautions (5.4)*]
- Pre-existing pulmonary vascular congestion or pulmonary edema [see *Warnings and Precautions (5.5)*]
- Active intracranial bleeding except during craniotomy.

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, hypotension and dyspnea resulting in cardiac arrest and death have been reported with Mannitol Injection [see *Adverse Reactions (6)*].

Stop the infusion immediately if signs or symptoms of a suspected hypersensitivity reaction develop. Initiate appropriate therapeutic countermeasures as clinically indicated.

5.2 Renal Complications Including Renal Failure

Renal complications, including irreversible renal failure have been reported in patients receiving mannitol. Reversible, oliguric acute kidney injury has occurred in patients with normal pretreatment renal function who received large intravenous doses of mannitol. Although the osmotic nephrosis associated with mannitol administration is in principle reversible, osmotic nephrosis in general is known to potentially proceed chronic or even end-stage renal failure. Monitor renal function closely, including signs of urine output reduction, during Mannitol Injection infusion. Patients with pre-existing renal disease, patients with conditions that put them at high risk for renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk of renal failure following administration of Mannitol Injection. Avoid concomitant administration of nephrotoxic drugs (e.g., aminoglycosides) or other diuretics with Mannitol Injection, if possible [see *Drug Interactions (7.1, 7.2)*].

Patients with oliguric acute kidney injury who subsequently develop anuria while receiving mannitol are at risk of congestive heart failure, pulmonary edema, hypertensive crisis, coma and death.

During and following Mannitol Injection infusion for the reduction in intracranial pressure, monitor the patient clinically and review laboratory tests for changes in fluid and electrolyte status. Discontinue Mannitol Injection if renal function worsens [see *Warnings and Precautions (5.5)*].

5.3 Central Nervous System (CNS) Toxicity

CNS toxicity manifested by, e.g., confusion, lethargy, coma has been reported in patients treated with mannitol, some resulting in death, in particular in the presence of impaired renal function CNS toxicity may result from high serum mannitol concentrations, serum hyperosmolarity resulting in intracellular dehydration within CNS, hyponatremia or other disturbances of electrolyte and acid/base balance secondary to mannitol administration [see *Warnings and Precautions (5.4)*].

At high concentrations, mannitol may cross the blood brain barrier and interfere with the ability of the brain to maintain the pH of the cerebrospinal fluid especially in the presence of acidosis.

In patients with preexisting compromise of the blood brain barrier, the risk of increasing cerebral edema (general and focal) associated with repeated or continued use of Mannitol Injection must be individually weighed against the expected benefits.

A rebound increase of intracranial pressure may occur several hours after the infusion. Patients with a compromised blood brain barrier are at increased risk.

Concomitant administration of neurotoxic drugs (e.g., aminoglycosides) with Mannitol Injection may potentiate neurotoxicity. Avoid concomitant use of neurotoxic drugs, if possible [see *Drug Interactions (7.3)*].

During and following Mannitol Injection infusion for the reduction in intracranial pressure, monitor the patient clinically and laboratory tests for changes in fluid and electrolyte status. Discontinue Mannitol Injection if CNS toxicity develops [see *Warnings and Precautions (5.5)*].

5.4 Fluid and Electrolyte Imbalances, Hyperosmolarity

Depending on dosage and duration, administration of Mannitol Injection may result in hypervolemia leading to or exacerbating existing congestive heart failure. Accumulation of mannitol due to insufficient renal excretion increases the risk of hypervolemia.

Mannitol-induced osmotic diuresis may cause or worsen dehydration/hypovolemia and hemoconcentration. Administration of Mannitol Injection may also cause hyperosmolarity [*see Description (11)*].

Depending on dosage and duration of administration, electrolyte and acid/base imbalances may also result from transcellular shifts in water and electrolytes, osmotic diuresis and/or other mechanisms. Such imbalances may be severe and potentially fatal.

Imbalances that may result from Mannitol Injection administration include:

- Hyponatremia, dehydration and hemoconcentration
- Hyponatremia, which can lead to headache, nausea, seizures, lethargy, coma, cerebral edema, and death. Acute symptomatic hyponatremic encephalopathy is considered a medical emergency.
- Hypo/hyperkalemia. The development of electrolyte imbalances (e.g., hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (e.g., digoxin, agents that may cause QT prolongation, neuromuscular blocking agents) [*see Drug Interactions (7.4)*].
- Other electrolyte disturbances
- Metabolic acidosis/alkalosis

Pediatric patients less than two years of age, particularly preterm and term neonates, may be at higher risk for fluid and electrolyte abnormalities following Mannitol Injection administration due to decreased glomerular filtration rate and limited ability to concentrate urine [*see Use in Specific Populations (8.4)*].

During and following Mannitol Injection infusion for the reduction in intracranial pressure, monitor fluid, acid-base balance and electrolyte status and discontinue Mannitol Injection if imbalances occur [*see Warnings and Precautions (5.5)*].

5.5 Monitoring/Laboratory Tests

During and following infusion of Mannitol Injection for reduction of intracranial pressure and monitor:

- serum osmolality, serum electrolytes (sodium, potassium, calcium, and phosphate) and acid base balance
- the osmol gap
- signs and symptoms of hypo- or hypervolemia, including urine output
- renal, cardiac, and pulmonary function
- intracranial pressure

Discontinue Mannitol Injection if renal, cardiac, or pulmonary status worsens or CNS toxicity develops [*see Contraindications (4)*].

5.6 Infusion Site Reactions

The infusion of hypertonic solutions through a peripheral vein, including Mannitol Injection may result in peripheral venous irritation, including phlebitis. Other severe infusion site reactions, such as compartment syndrome and swelling associated with extravasation, can occur with administration of Mannitol Injection [*see Adverse Reactions (6)*]. Administration through a large central vein is preferred with mannitol [*see Dosage and Administration (2.1)*].

5.7 Interference with Laboratory Tests

High concentrations of mannitol can cause false low results for inorganic phosphorus blood concentrations [see *Drug Interactions (7.6)*].

Mannitol may produce false positive results in tests for blood ethylene glycol concentrations [see *Drug Interactions (7.6)*].

6 ADVERSE REACTIONS

The following adverse reactions from voluntary reports or clinical studies have been reported with Mannitol Injection. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- *Hypersensitivity reactions*: anaphylaxis, hypotension, dyspnea, hypertension, pyrexia, chills, sweating, urticaria/rash, pruritus [see *Warnings and Precautions (5.1)*]
- *Renal Failure*: acute kidney injury, osmotic nephrosis, azotemia, anuria, hematuria, oliguria, polyuria, urinary retention [see *Warnings and Precautions (5.2)*]
- *CNS Toxicity*: coma, seizures, confusion, lethargy; rebound increase in intracranial pressure; dizziness, headache [see *Warnings and Precautions (5.3)*]
- *Fluid and Electrolyte Imbalances*: hypovolemia (dehydration), hypervolemia, peripheral edema, hyponatremia, hypernatremia, hyperkalemia, hypokalemia; metabolic acidosis [see *Warning and Precautions (5.4)*]
- *Infusion Site Reactions*: venous thrombosis, phlebitis, inflammation, pain, rash, erythema, pruritus; compartment syndrome and swelling associated with extravasation [see *Warnings and Precautions (5.6)*]
- *Cardiac and Respiratory Disorders*: cardiac arrest, congestive cardiac failure, pulmonary edema, palpitations, tachycardia, angina-like chest pain
- *Musculoskeletal Disorders*: musculoskeletal stiffness, myalgia
- *Gastrointestinal Disorders*: thirst, dry mouth, nausea, vomiting
- *General Disorders*: asthenia, malaise

7 DRUG INTERACTIONS

7.1 Nephrotoxic Drugs

Concomitant administration of nephrotoxic drugs (e.g., aminoglycosides, cyclosporine) increases the risk of renal failure following administration of mannitol. Avoid use of nephrotoxic drugs with Mannitol Injection, if possible [see *Warnings and Precautions (5.2)*].

7.2 Diuretics

Concomitant administration of other diuretics may potentiate the renal toxicity of mannitol. Avoid use of other diuretics with Mannitol Injection, if possible [see *Warnings and Precautions (5.2)*].

7.3 Neurotoxic Drugs

Concomitant administration of systemic neurotoxic drugs (e.g., aminoglycosides) with Mannitol Injection may potentiate the CNS toxicity of mannitol. Avoid concomitant administration of neurotoxic drugs with mannitol [see *Warnings and Precautions (5.3)*].

7.4 Drugs Affected by Electrolyte Imbalances

The development of electrolyte imbalances (e.g., hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (e.g., digoxin, drugs that prolong the QT interval, neuromuscular blocking agents) [see *Warnings and Precautions* (5.4)]. During and following Mannitol Injection infusion, monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens [see *Warnings and Precautions* (5.5)].

7.5 Renally Eliminated Drugs

Mannitol may increase the elimination, and decrease the effectiveness of treatment with, drugs that undergo significant renal elimination. Concomitant administration of mannitol with lithium may initially increase the elimination of lithium but may also increase the risk of lithium toxicity in patients who develop hypovolemia or renal impairment. Consider holding lithium therapy during treatment with Mannitol Injection. If lithium therapy cannot be held, monitor serum lithium concentrations frequently for signs of lithium toxicity. Mannitol therapy may increase the elimination of digoxin leading to a potential decrease in effectiveness of the treatment. Monitor digoxin serum concentrations.

7.6 Interference with Laboratory Tests

High concentrations of mannitol can cause false low results for inorganic phosphorus blood concentrations when an assay based on the conversion of phosphate (orthophosphate) to the phosphomolybdate complex is used [see *Warnings and Precautions* (5.7)].

Mannitol may produce false positive results in tests for blood ethylene glycol concentrations in which mannitol is initially oxidized to an aldehyde [see *Warnings and Precautions* (5.7)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

The available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (*see Data*). No adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal infusion of mannitol.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Human Data

Published literature reports the presence of mannitol in amniotic fluid when mannitol is administered to pregnant women during the third trimester of pregnancy.

8.2 Lactation

Risk Summary

There are no data on the presence of mannitol in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Mannitol Injection and any potential adverse effects on the breastfed infant from Injection or from the underlying maternal condition.

8.4 Pediatric Use

Mannitol Injection is approved for use in the pediatric population for the reduction of intracranial and intraocular pressure. Studies have not defined the optimal dose of Mannitol Injection in the pediatric population. The safety profile for mannitol use in pediatric patients is similar to adults at dosages described in labeling. However, pediatric patients less than two years of age, particularly preterm and term neonates, may be at higher risk for fluid and electrolyte abnormalities following Mannitol Injection administration due to decreased glomerular filtration rate and limited ability to concentrate urine [see *Warnings and Precautions (5.4)*].

8.5 Geriatric Use

Mannitol is known to be substantially excreted by the kidney and the risk of adverse reactions to this drug may be greater in elderly patients with impaired renal function. Evaluate the renal, cardiac, and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of Mannitol Injection [see *Warnings and Precautions (5.2, 5.3, 5.4, 5.5)*].

8.6 Renal Impairment

Patients with pre-existing renal disease, patients with conditions that put them at high risk of renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk of renal failure with administration of mannitol. Evaluate the renal, cardiac, and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of Mannitol Injection [see *Warnings and Precautions (5.2, 5.3, 5.4, 5.5)*].

10 OVERDOSAGE

Signs and symptoms of overdose with Mannitol Injection include renal failure and acute kidney injury, hypo/hypervolemia, hyperosmolarity and electrolyte imbalances, CNS toxicity (e.g., coma, seizures), some of which can be fatal [see *Warnings and Precautions (5.2, 5.3, 5.4)*].

Management of overdosage with Mannitol Injection is symptomatic and supportive. Discontinue the infusion and institute appropriate corrective measures with particular attention to renal, cardiac and pulmonary systems. Correct fluid and electrolyte imbalances.

Mannitol Injection is dialyzable (hemodialysis and peritoneal dialysis), hemodialysis may increase Mannitol Injection elimination.

11 DESCRIPTION

Mannitol Injection, USP is a sterile, nonpyrogenic solution of mannitol in water for injection available in a concentration of 20% in flexible plastic containers.

The content and characteristics of the available concentration is as follows:

Concentration (%)	g/100 mL	mOsmol/liter (calc.)	pH*
20	20	1098	6.3 (4.5 to 7.0)

* may contain sodium bicarbonate for pH adjustment.

Mannitol is eliminated primarily via the kidneys in unchanged form. Mannitol is filtered by the glomeruli, exhibits less than 10% of tubular reabsorption, and is not secreted by tubular cells. Following intravenous administration, approximately 80% of an administered dose of mannitol is estimated to be excreted in the urine in three hours with lesser amounts thereafter.

Specific Populations

Patients with Renal Impairment

In patients with renal impairment, the elimination half-life of mannitol is prolonged. In a published study, in patients with renal impairment including acute renal failure and end stage renal failure, the elimination half-life of mannitol was estimated at about 36 hours, based on serum osmolarity. In patients with renal impairment on dialysis, the elimination half-life of mannitol was reduced to 6 and 21 hours during hemodialysis and peritoneal dialysis, respectively. [see *Use in Specific Populations (8.6)*, *Overdosage (10)*].

16 HOW SUPPLIED/STORAGE AND HANDLING

Mannitol Injection is a clear and colorless solution supplied in single-dose containers as follows:

Unit of Sale	Concentration	Each
NDC 0409-7715-03 NDC 0990-7715-03 Case containing 12	20% (0.2 g/mL) mannitol, USP	NDC 0409-7715-13 NDC 0990-7715-13 500 mL Flexible Container
NDC 0409-7715-02 NDC 0990-7715-02 Case containing 24	20% (0.2 g/mL) mannitol, USP	NDC 0409-7715-12 NDC 0990-7715-12 250 mL Flexible Container

ICU Medical is transitioning NDC codes from “0409” to “0990” labeler code. Both NDC codes are expected to be in the market for a period of time.

Protect from freezing. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

17 PATIENT COUNSELING INFORMATION

Inform patients, caregivers, or home healthcare providers of the following risks of Mannitol Injection:

- Hypersensitivity Reactions [see *Warnings and Precautions (5.1)*]
- Renal Failure [see *Warnings and Precautions (5.2)*]
- CNS Toxicity [see *Warnings and Precautions (5.3)*]
- Fluid and Electrolyte Imbalances, Hyperosmolarity [see *Warnings and Precautions (5.4)*]
- Infusion Site Reactions [see *Warnings and Precautions (5.6)*]

EN-4730

Manufactured by:

ICU Medical, Inc., Lake Forest, Illinois, 60045 USA

icumedical